Medipixel develops the MPXA, a software as a medical device that utilizes deep learning algorithms to perform real-time quantitative analysis of cardiovascular conditions during catheterization procedures. This technology enables intervention surgeons to receive accurate diagnostic insights in an average of 1.8 seconds, enhancing decision-making and improving patient outcomes.
Funding
$22.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
During cardiovascular catheterization procedures, interventional surgeons often face challenges in rapidly and accurately assessing the patient's condition, which can impact decision-making and procedural outcomes. Traditional methods may be time-consuming or lack the precision needed for optimal intervention.
Solution
Medipixel develops MPXA, a software as a medical device (SaMD) that leverages deep learning to provide real-time quantitative analysis of cardiovascular conditions during catheterization. MPXA seamlessly integrates into the cath lab workflow, providing clinicians with highly accurate analysis in an average of 1.8 seconds. This rapid analysis supports improved decision-making during procedures. The AI-powered system automates the analysis process, delivering results without disrupting the workflow.
Target Audience
The primary target audience includes interventional cardiologists and surgeons performing catheterization procedures, as well as clinical researchers in the cardiovascular field.
Features
- AI-powered, fully automated quantitative analysis of cardiovascular conditions
- Real-time analysis with results available in an average of 1.8 seconds
- Seamless integration into existing cath lab workflows
- High accuracy in cardiovascular condition assessment
- MPXA CoreLab: Retrospective quantitative analysis of cardiovascular images for research purposes (not a medical device)
- FDA 510(k) clearance